Corporate Development

Advanced BioHealing intends to further its position as a leader in the field of regenerative medicine. The key elements of this strategy are to:

• Drive further adoption of Dermagraft for the treatment of DFUs in the United States.
• Commercialize Dermagraft internationally.
• Invest in manufacturing and research and development.
• Broaden the Company’s product portfolio through internal and external development initiatives.

Advanced BioHealing may selectively in-license or acquire complementary products and technologies that will allow the Company to leverage its commercialization and manufacturing experience.

For more information, please contact Dean Tozer, Senior Vice President of Corporate Development.

Important Safety Information about Dermagraft®

Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Refer to Dermagraft Directions for Use for more information. Results may vary and not all patients will achieve complete wound closure with Dermagraft. In the pivotal trial, a 64% relative increase in complete wound closure was seen in the Dermagraft-treated patients; 30.0% of Dermagraft and 18.3% of conventional therapy patients achieved complete wound closure at 12 weeks. The most frequently reported adverse events experienced by patients in the Dermagraft group (terms ≥ 5%) included infection, accidental injury, skin dysfunction/blister, flu syndrome, osteomyelitis, surgeries involving study ulcer, wound enlargement/skin ulcer, cellulitis and peripheral edema/localized swelling. These adverse events were similar to those seen in the control group.